PF-06865571 combined with PF-05221304 showed good efficacy and safety in a phase II trial for the treatment of nonalcoholic steatohepatitis (NASH) [66, 75], suggesting that the development of multitarget inhibitors is the future direction for drugs targeting DGAT2 and ACC1/2 (Fig. 3). The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatohepatitis.